awmsg logo



capsaicin (Qutenza®)


Reference No. 823

Publication date:
08/03/2012


Last review date:
30/09/2016

Appraisal information

capsaicin (Qutenza®) 179 mg cutaneous patch


Company: Astellas Pharma Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 04/01/2012
AWMSG meeting date: 08/02/2012
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0412
Ministerial ratification: 08/03/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Capsaicin patch (Qutenza®) is not recommended for use alone for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults. Capsaicin patch (Qutenza®) is recommended as an option for restricted use within NHS Wales for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults in combination with other medicinal products for pain and in patients who have not received adequate benefit from, or are intolerant to, alternative conventional treatments. The company submission provided evidence on the cost effectiveness of capsaicin patch (Qutenza®) as an add-on treatment in patients who were refractory to or intolerant of usual first or second line treatments. Capsaicin patches (Qutenza®) should be administered by healthcare professionals who have completed the approved training and in a specialist clinic setting. AWMSG is of the opinion that capsaicin patch (Qutenza®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download